Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9371-9379

  Varghese, Susan ^a,b   Rabkin, Samuel D ^a,b   Nielsen, G Petur ^a   MacGarvey, Usha ^a   Liu, Renbin ^a,b   Martuza, Robert L ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 4 CHLORO 3 INDOLYL BETA DEXTRO GALACTOPYRANOSIDE; BROMINE DERIVATIVE; CHLORINE DERIVATIVE; INDOLE DERIVATIVE; INTERLEUKIN 12; ONCOLYTIC HERPES SIMPLEX VIRUS NV1023; ONCOLYTIC HERPES VIRUS; ONCOLYTIC HERPES VIRUS NV1042; PYRANOSIDE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DNA DETERMINATION; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE; GENE EXPRESSION; GENE LAC Z; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; STAINING; SYSTEMIC THERAPY; TRANSGENIC MOUSE; TUMOR CELL; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOCARCINOMA; ANIMALS; CELL GROWTH PROCESSES; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; SIMPLEXVIRUS;

EID: 35148841515     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0674     Document Type: Article

References (48)

1. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005;12:141-61.
2. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76.
3. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854-6.
4. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002;9:967-78.
5. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
6. Hu JC, Davis CJ, Graham NJ, et al. Results of a phase I/II clinical trial with Oncovex-GMCSF, a second generation oncolytic herpes simplex virus [abstract]. Am Soc Gene Ther Annual Meeting. 2005.
7. Kuruppu D, Tanabe KK. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther 2005;4:524-31.
8. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999;10:385-93.
9. Thomas DL, Fraser NW. HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol Ther 2003;8:543-51.
10. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292-303.
11. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-43.
12. Varghese S, Newsome JT, Rabkin SD, et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001;12:999-1010.
13. Mashour GA, Moulding HD, Chahlavi A, et al. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp Neurol 2001;169:64-71.
14. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuz RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999;10:2237-43.
15. Cozzi PJ, Burke PB, Bhargav A, et al. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 2002;53:95-100.
16. Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector g47δ in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res 2005;11:7886-90.
17. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 2006;13:253-65.
18. Jorgensen TJ, Katz S, Wittmack EK, et al. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 2001;3:451-6.
19. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
20. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-102.
21. Wong RJ, Patel SG, Kim S, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001;12:253-65.
22. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-14.
23. Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res 2006;12:2919-27.
24. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Vols. 1 to 3. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
25. Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305.
26. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
27. Choi J, Shendrik I, Peacocke M, et al. Expression of senescence- associated β-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology 2000;56:160-6.
28. Castro P, Giri D, Lamb D, Ittmann M. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 2003;55:30-8.
29. Condon MS. The role of the stromal microenvironment in prostate cancer. Semin Cancer Biol 2005;15:132-7.
30. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-83.
31. Li H, Gerald WL, Benezra R. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res 2004;64:6137-43.
32. Asamoto M, Hokaiwado N, Cho YM, Shirai T. Effects of genetic background on prostate and taste bud carcinogenesis due to SV40 T antigen expression under probasin gene promoter control. Carcinogenesis 2002;23:463-7.
33. Suttie A, Nyska A, Haseman JK, Moser GJ, Hackett TR, Goldsworthy TL. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol Pathol 2003;31:31-8.
34. Suttie AW, Dinse GE, Nyska A, Moser GJ, Goldsworthy TL, Maronpot RR. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse. Toxicol Pathol 2005;33:386-97.
35. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
36. Hsu CX, Ross BD, Chrisp CE, et al. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol 1998;160:1500-05.
37. Kasper S, Smith JA, Jr. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol 2004;172:12-9.
38. Jarnagin WR, Zager JS, Klimstra D, et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003;10:215-23.
39. Bennett JJ, Malhotra S, Wong RJ, et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 2001;233:819-26.
40. Hellums EK, Markert JM, Parker JN, et al. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro-oncol 2005;7:213-24.
41. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Marker JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000;97:2208-13.
42. Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/ SV40 T-antigen transgenic mice. Cancer Res 2005;65:1532-40.
43. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
44. Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis 1997;1:23-35.
45. Wong RJ, Chan MK, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004;10:251-9.
46. Derubertis BG, Stiles BM, Bhargava A, et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther 2007;14:590-7.
47. Wong RJ, Chan MK, Yu Z, et al. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004;10:4509-16.
48. Weiss DJ, Liggitt D, Clark JG. In situ histochemical detection of β-galactosidase activity in lung: assessment of X-Gal reagent in distinguishing lacZ gene expression and endogenous β-galactosidase activity. Hum Gene Ther 1997;8:1545-54.